Newsroom | Co-Diagnostics, Inc.

Newsroom

Month Year

Media Resources

Mar 2, 2021

Co-Diagnostics New Rapid PCR Point-of-Care and at Home Testing Platform to Detect Covid-19 and Other Diseases Using CoPrimer™ Technology

Proprietary platform includes countertop device being developed for Co-Diagnostics by world experts in rapid PCR

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today the development of a new...
- Photos 1
Feb 25, 2021

Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based COVID-19 PCR Test Through Walgreens Find Care®

Clinical Reference Laboratory's FDA-authorized saliva-based PCR test uses technology developed by Co-Diagnostics to detect SARS-CoV-2

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that laboratory partner Clinical...
Feb 23, 2021

Co-Diagnostics, Inc. Announces New Chief Financial Officer

Company also elevates in-house Senior VP of Biochemistry to Chief Scientific Officer

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is pleased to welcome Brian Brown
Feb 16, 2021

Co-Diagnostics, Inc. to Present on Direct Saliva Testing Technology at Molecular Med Tri-Con

Company believes direct saliva to play a key role in high throughput, point of care, and at home applications

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it will be presenting on direct...
Jan 28, 2021

Co-Diagnostics Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test

The Company's Logix Smart™ SARS-CoV-2 DS (Direct Saliva) test is designed to reduce sample processing time and cost by eliminating the extraction process

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it...
Jan 7, 2021

Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that...
Jan 6, 2021

Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that,...
Dec 22, 2020

Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform

Proprietary Company design process facilitates rapid response in detecting mutation of a new coronavirus strain circulating in the UK

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...
Dec 14, 2020

Co-Diagnostics Announces Milestone of Over 10 Million COVID-19 Tests Sold

Company anticipates Q4 revenue will significantly exceed previous quarter

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has...
Nov 25, 2020

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...
Nov 17, 2020

Co-Diagnostics, Inc. Receives CE Markings for "ABC" and SARS-CoV-2 2-Gene Multiplex Tests

New tests expand global reach of Company COVID-19 test menu

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ ABC...
Nov 16, 2020

Co-Diagnostics, Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07

Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the...
Nov 11, 2020

Co-Diagnostics, Inc. CoPrimers™ Shown to be Effective in COVID-19 Saliva PCR Tests Without Sample Extraction

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that a recent Company...
Nov 10, 2020

Co-Diagnostics, Inc. Announces Q3 2020 Earnings Release Date and Earnings Webcast

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will release its...
Nov 2, 2020

Co-Diagnostics, Inc. to Amend Q2 2020 Form 10-Q to Show $0.51 Net Income per Share

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that following the...
Oct 2, 2020

Co-Diagnostics, Inc. Logix Smart Kit to be Used with Newly Authorized Saline Oral Rinse Collection

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Access Genetics, LLC dba...
Sep 24, 2020

Co-Diagnostics, Inc. Provides Update on "ABC" Test for Influenza A, Influenza B, and COVID-19

Company expects to begin taking orders from US CLIA labs first week of October 2020

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its Logix Smart™ ABC Test...
Sep 11, 2020

Co-Diagnostics, Inc. Announces Details to Access Presentation at H.C. Wainwright Global Investment Conference

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced the access details for CEO Dwight...
Sep 8, 2020

Co-Diagnostics, Inc. Enters into Agreement with Arches Research to Expand COVID-19 Testing Services

Salt Lake City, Utah – September 8, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
Sep 1, 2020

Co-Diagnostics, Inc. Issues Operational Update

Salt Lake City, Utah – September 1, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
Aug 25, 2020

Co-Diagnostics, Inc. To Discuss Recent Company Growth and Upcoming Expansion Plans at H.C. Wainwright Global Investment Conference

Salt Lake City, Utah – August 25, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
Aug 20, 2020

Co-Diagnostics, Inc. Receives Enhanced U.S. Patent Protection for CoPrimer™ Technology Used in COVID-19 Test

Salt Lake City, Utah – August 20, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Aug 13, 2020

Co-Diagnostics, Inc. Announces Q2 2020 Results on Form 10-Q

Company reports robust sales of COVID-19 tests and net income per common share of $0.43

Salt Lake City, Utah – August 13, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Aug 11, 2020

Co-Diagnostics, Inc. Announces Q2 2020 Earnings Release Date and Earnings Webcast

Salt Lake City, Utah – August 11, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Aug 7, 2020

Co-Diagnostics, Inc. Logix Smart™ COVID-19 Test Authorized for Use in Australia

Salt Lake City, Utah – August 7, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Aug 3, 2020

Co-Diagnostics, Inc. Technology to be Used in FDA-Authorized Self-Collected COVID-19 Saliva Test

Salt Lake City, Utah – August 3, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Jun 9, 2020

Co-Diagnostics, Inc. to Join Russell 2000® and Russell 3000® Indexes

Salt Lake City, Utah – June 9, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 27, 2020

Co-Diagnostics, Inc. to Present at COVID-19 Virtual Conference Hosted by Maxim Group on May 27, 2020

Salt Lake City, Utah – May 27, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 26, 2020

Co-Diagnostics, Inc. COVID-19 Test Successfully Used to Identify Coronavirus in Cancer Tissue

Tissue from presymptomatic patient in Italy was found to contain SARS-CoV-2 using Company’s Logix Smart™ COVID-19 test kit

Salt Lake City, Utah – May 26, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 14, 2020

Co-Diagnostics, Inc. Announces Q1 2020 Results and Provides Mid-Second Quarter Update

Company reports robust sales of COVID-19 tests as Co-Diagnostics generates net profit through middle of second quarter

Salt Lake City, Utah – May 14, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 14, 2020

Co-Diagnostics, Inc. Releases Prepared Remarks for First Quarter 2020 Conference Call

Salt Lake City, Utah – May 12, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 12, 2020

Co-Diagnostics, Inc. Announces Q1 2020 Earnings Release Date and Earnings Call

Salt Lake City, Utah – May 12, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic...
May 4, 2020

Co-Diagnostics, Inc. Announces Government Approvals and Increased Orders for COVID-19 Test Kits

Salt Lake City, Utah – May 4, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
May 1, 2020

Co-Diagnostics, Inc. Releases COVID-19 Test Performance Data: Consistently Demonstrates 100% Sensitivity and 100% Specificity Across Independent Evaluations

Salt Lake City, Utah – May 1, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
Apr 20, 2020

Co-Diagnostics, Inc. Announces Expansion of COVID-19 Test Orders in the United States

Salt Lake City, Utah – April 20, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Apr 16, 2020

Co-Diagnostics, Inc. COVID-19 Test Technology Validated for Use on Saliva Samples

Salt Lake City, Utah – April 16, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Apr 14, 2020

Co-Diagnostics, Inc Contracts with Promega Corp for COVID-19 Test Manufacturing as Company Expands Domestic Customer Base

Salt Lake City, Utah – April 14, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,
Apr 6, 2020

Co-Diagnostics, Inc Receives FDA Emergency Use Authorization for COVID-19 Test

Salt Lake City, Utah – April 6, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 31, 2020

Co-Diagnostics, Inc. Reports 2019 Year-End Financial Results and Progress Updates

Salt Lake City, Utah – March 31, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests,...
Mar 20, 2020

Co-Diagnostics, Inc Completes Successful Clinical Evaluation Required for FDA Emergency Use Authorization

Company accelerates U.S. sales of COVID-19 test pursuant to new FDA policy

Salt Lake City, Utah – March 19, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 19, 2020

Co-Diagnostics JV CoSara First Indian Company to Receive License for COVID-19 Diagnostic

Salt Lake City, Utah – March 19, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 17, 2020

FDA Policy Change to Allow Rapid Domestic Expansion of Co-Diagnostics COVID-19 Test

Salt Lake City, Utah – March 17, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 12, 2020

Co-Diagnostics, Inc Chief Scientific Officer to Address Bipartisan Commission on Biodefense in Washington, D.C.

***UPDATE*** Due to travel restrictions and health concerns, the conference has been canceled. We will post any further updates here. Salt Lake City, Utah – March 12, 2020 – Co-Diagnostics,...
Mar 5, 2020

Co-Diagnostics, Inc. Reports Additional Demand for Coronavirus Test Shipments

Salt Lake City, Utah – March 5, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced...
Mar 3, 2020

Co-Diagnostics, Inc. Invited to Speak on Coronavirus at Molecular Med Tri-Con in San Francisco

Salt Lake City, Utah – March 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests and that...
Mar 2, 2020

Co-Diagnostics Announces Closing of $4.2 Million Registered Direct Offering Priced At-the-Market

Salt Lake City, Utah – March 02, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today...
Feb 27, 2020

Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-the-Market

Salt Lake City, Utah – February 27, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today...
Feb 24, 2020

Co-Diagnostics, Inc Receives CE Mark for Novel Coronavirus Test

Logix Smart™ COVID-19 Test now available for export from the United States as a CE-marked IVD

Salt Lake City, Utah – February 24, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
Feb 20, 2020

Co-Diagnostics Completes Submission of CE Marking Registration for COVID-19 Coronavirus Test

Company’s new Logix Smart™ COVID-19 Test expected to be available with CE marking in February 2020

Salt Lake City, Utah – February 20, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...
Feb 19, 2020

Co-Diagnostics Announces New Vector Control Orders and Continued Progress Toward Regulatory Clearance for Coronavirus Test

Salt Lake City, Utah – February 19, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests,...

Show per page